Aug 02, 2018 1:09pm EDT CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018
Jul 12, 2018 9:00am EDT CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH
Jun 25, 2018 12:08pm EDT CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions
Jun 06, 2018 9:45am EDT CohBar to Hold 2018 Annual Shareholder Meeting and Investor Update, June 19, 2018
May 29, 2018 9:00am EDT CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions